Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects.

B Dahlén, D J Margolskee, O Zetterström, S E Dahlén

Department of Thoracic Medicine, Karolinska Hospital, Stockholm, Sweden.

BACKGROUND--The cysteinyl leukotrienes (LTC4, LTD4, and LTE4) have been shown to mediate airway obstruction evoked by several factors which trigger asthmatic reactions--for example, allergen and exercise. Accordingly, drugs which block the action or formation of these leukotrienes are being evaluated as a new treatment of asthma. Elevated production of leukotrienes has been reported in asthmatic subjects who are intolerant to aspirin and related nonsteroidal anti-inflammatory drugs. In this study the influence of the specific leukotriene receptor antagonist MK-0679 was tested on basal airway function in asthmatic patients with documented aspirin intolerance. METHODS--The eight subjects in the study had a mean baseline FEV1 of 78% predicted (range 58-99%) and six required treatment with inhaled glucocorticosteroids (400-1200 micrograms budesonide/beclomethasone daily). On two separate days the subjects received either 825 mg MK-0679 or placebo, orally in a double blind, randomised, crossover design. RESULTS--The leukotriene antagonist MK-0679 caused bronchodilation which lasted for at least nine hours. The average peak improvement in FEV1 was 18% above the predrug baseline, but the bronchodilator response varied between 34% and 5% and was found to correlate strongly with the severity of asthma and aspirin sensitivity. CONCLUSIONS--The findings indicate that ongoing leukotriene production may be one cause of persistent airway obstruction in aspirin sensitive asthmatic subjects and that they may benefit from treatment with a leukotriene receptor antagonist.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Leukotrienes and aspirin induced asthma.

T H Lee and P E Christie
Thorax 1993 48: 1189-1190. [PDF]

This article has been cited by other articles:

• RODGER, I. W. (2000). From Bench to Bedside . The Hurdles of Discovering a New Leukotriene Receptor Antagonist. Am. J. Respir. Crit. Care Med. 161: S7-10 [Full Text]  
• DAHLEN, B. (2000). Treatment of Aspirin-intolerant Asthma with Antileukotrienes. Am. J. Respir. Crit. Care Med. 161: S137-141 [Full Text]  
• (1999). Leukotriene-receptor antagonists and related compounds. CMAJ 161: s31-34 [Full Text]  
• Drazen, J. M., Israel, E., O'Byrne, P. M. (1999). Treatment of Asthma with Drugs Modifying the Leukotriene Pathway. NEJM 340: 197-206 [Full Text]  
• DRAZEN, J. M. (1998). Leukotrienes as Mediators of Airway Obstruction. Am. J. Respir. Crit. Care Med. 158: S193-S200 [Abstract] [Full Text]  
• DAHLEN, B., NIZANKOWSKA, E., SZCZEKLIK, A., ZETTERSTROM, O., BOCHENEK, G., KUMLIN, M., MASTALERZ, L., PINIS, G., SWANSON, L. J., BOODHOO, T. I., WRIGHT, S., DUBE, L. M., DAHLEN, S.-E. (1998). Benefits from Adding the 5-Lipoxygenase Inhibitor Zileuton to Conventional Therapy in Aspirin-intolerant Asthmatics. Am. J. Respir. Crit. Care Med. 157: 1187-1194 [Abstract] [Full Text]  
• DRAZEN, J. (1997). Clinical Pharmacology of Leukotriene Receptor Antagonists and 5-Lipoxygenase Inhibitors. Am. J. Respir. Crit. Care Med. 157: 233S-237 [Abstract] [Full Text]  
• Smith, L. J. (1996). Leukotrienes in Asthma: The Potential Therapeutic Role of Antileukotriene Agents. Arch Intern Med 156: 2181-2189 [Abstract]  
• Israel, E., Cohn, J., Dube, L., Drazen, J. M., Zileuton Clinical Trial Group, , Ratner, P., Pleskow, W., DeGraff, A. Jr, Chervinsky, P., Wasserman, S., Nelson, H., Yocum, M., Dockborn, R. J., Siegel, S. C., Aldrich, T., Karpel, J., Busse, W., Lazarus, S., Menendez, R., Segal, A. T., Thompson, A., Weinstein, A., Barbee, R., Leff, A., Strek, M., Lopez, M., Charous, B. L., Hutt, D., Murray, J. J., Tinkelman, D., Ilowite, J., Kaiser, H. B., Bowling, B. T., Grossman, J., Edwards, T., Fish, J., VanBavel, J. H., Fox, R., Wanderer, A. A., Winder, J. A., Zeitz, H. J., Lee, T., Scharer, L., Hanrahan, J. P., Lancaster, J., Manski, R., Bialek-Smith, S., Swanson, L. J. (1996). Effect of Treatment With Zileuton, a 5-Lipoxygenase Inhibitor, in Patients With Asthma: A Randomized Controlled Trial. JAMA 275: 931-936 [Abstract]